Skip navigation
Dr. Benjamin Schrank explains his recent research on a first-in-class antibody-drug conjugate that…
0:00 / 0:31

Dr. Benjamin Schrank explains his recent research on a first-in-class antibody-drug conjugate that…

UT MD Anderson

@UTMDAnderson142K followers

Visit on X
77 likesDownloadOriginal post

11,321 views #ASTRO24 #EndCancer

Dr. Benjamin Schrank explains his recent research on a first-in-class antibody-drug conjugate that is designed to trigger an immune response, as a complementary strategy to radiation therapy. Read more: Benjamin Schrank, MD, PhD #ASTRO24 #EndCancer

4 Comments

Comments from the original post on X (Twitter)

  • Betty Y.S. Kim, MD, PhD, FRCSC, FAIMBE's profile picture

    @BettyKimLab

    @BenjaminSchrank @BenjaminSchrank is without a doubt one of the very best physician scientist trainee I have ever encountered. Quadruple threat: great scientist, leadership skills, gifted educator and super kind/humble. Truly exceptional. He’s also on the job market. So proud!

    20 likes

  • Benjamin Schrank, MD, PhD's profile picture

    @BenjaminSchrank

    Thankful to @BettyKimLab and @wenjiang_nano for their continued mentorship and support!

    10 likes

  • Raffaele Di Giacomo, PhD's profile picture

    @sciqst

    Dr. Schrank's research on the antibody-drug conjugate sounds promising, especially as a complement to radiation therapy. By triggering an immune response, it could enhance the overall effectiveness of cancer treatments – potentially improving patient outcomes. How does this conjugate specifically interact with the immune system compared to other immunotherapies? For those interested in more detailed biomedical insights or reviews, check out – your one-stop platform for every biomedical question. #Medicine #CancerResearch #Immunotherapy

  • Mother of Swans's profile picture

    @motherofswans

    @BenjaminSchrank 👏 LFG! Help me live! #NSCLC #EGFR #OligoBrainMets